PETALING JAYA: Pharmaniaga
LifeScience Sdn Bhd, the wholly-owned subsidiary of Pharmaniaga Bhd, has entered into a research collaboration agreement with BioNet-Asia Co Ltd, a Thai-French biotech vaccine company, for the development of a hexavalent vaccine.
Specifically for children, the vaccine is slated to be ready by the end of 2023 and commercialised by 2026.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
